A Phase II, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 (1 % and 2 %) Versus Placebo in Impetigo
Latest Information Update: 10 Jan 2015
At a glance
- Drugs LTX 109 (Primary)
- Indications Impetigo
- Focus Therapeutic Use
- Sponsors Lytix Biopharma
Most Recent Events
- 30 Apr 2014 New trial record